Scientists Search for Therapeutic Synergy in Primary Effusion Lymphoma

A rare and fatal form of aggressive B-cell lymphoma is Primary effusion lymphoma (PEL), which is caused by Kaposi's sarcoma-associated herpesvirus (KSHV).

The disease most commonly occurs in immunocompromised patients, such as those with HIV and the elderly. Because current treatment options are not effective, there is a great need for new PEL therapies.

Patient Survival in Non-Hodgkins Lymphoma may be Predicted by Epigenomic Abnormalities
Abnormal changes in the epigenetic mixing board can change the expression of genes in cancer, a University of Colorado Cancer Center study has revealed.

In this issue of the Journal of Clinical Investigation, Juan Carlos Ramos and colleagues at the University of Miami used an immunocompromised mouse model of PEL to determine the efficacy of Bortezomib/Vorinostat combination therapy, two drugs that are currently being used to treat multiple myeloma and cutaneous T cell lymphoma, respectively. They found that this treatment combination reactivated virus-induced cell lysis and induced PEL cell death, increasing the lifespan of mice with PEL tumors.

These findings indicate that this drug combination could potentially be beneficial in immunocompromised patients with KSHV-associated malignancies.

Source-Eurekalert

For Treating Relapsed Lymphomas, High-dose Vorinostat Effective
Cancer patients whose aggressive lymphomas have relapsed or failed to respond to the current front-line chemotherapy regimen now have an effective second line of attack against their disease.

Targeted Combinational Therapy For Deadly Lymphoma
US researchers are suggesting a new targeted combinational therapy to fight Diffuse large B-cell lymphoma (DLBCL). It is an aggressive non-Hodgkin’s lymphoma.

Burkitt’s Lymphoma - Symptoms - Signs - Diagnosis - Treatment - FAQs
Burkitt’s lymphoma is a rare type of non-hodgkin’s lymphoma that commonly affects children. It usually begins in the abdominal region.